Maternal RSV vaccine cuts infant hospitalisation risk by 81% in Australian study

What just happened

A prospective surveillance study just published in a major peer-reviewed journal has confirmed what the clinical trials promised — and confirmed it in Australia, with Australian hospitals, during an actual Australian RSV season.

The study tracked 1,012 infants hospitalised with acute respiratory illness across nine major Australian hospitals from March 2025 to February 2026. The finding: maternal RSV vaccination with Abrysvo reduced infant hospitalisation risk by 80.8% across the first six months of life. In infants under two months — the group most vulnerable to severe RSV — effectiveness against lower respiratory tract disease reached 86.3%.

For pregnant women who have been asking “but does this actually work here, in Australian hospitals, with Australian babies?” — this is the answer. It does.

Both-and

The numbers and why they matter

Respiratory syncytial virus is not a household name in the way whooping cough or measles is. It should be. RSV is the leading cause of hospitalisation in infants under twelve months in Australia, and in a newborn in the first weeks of life, a bronchiolitis episode can deteriorate quickly. There is no antiviral treatment for RSV. There is no specific therapy beyond oxygen, fluids, and supportive care. The only lever available before birth is the maternal vaccine.

The 81% hospitalisation reduction translates into real terms: in a cohort where you might otherwise expect ten infants to be admitted with RSV, vaccination is associated with approximately two. The 86% effectiveness against lower respiratory tract disease in infants under two months is the number that matters most, because those are the infants who end up in intensive care.

What distinguishes this study from the pre-approval trial data is the setting. A prospective surveillance study of hospitalised infants across nine Australian hospitals — with vaccine status confirmed through the Australian Immunisation Register — is the real-world equivalent of a phase 4 effectiveness study. The population is the actual population. The hospitals are the actual hospitals. The RSV strains circulating in the 2025–26 season were the actual strains.

The vaccination conversation

Some families will still have questions — about timing in pregnancy, about whether the risk of RSV has been overstated, about whether having another vaccine during pregnancy is reasonable. These are real questions and they deserve straightforward answers rather than reassurance dressed up as information.

On timing: Abrysvo sits alongside the pertussis booster that is routinely offered in the third trimester. Pertussis vaccination in pregnancy has been standard practice for years precisely because maternal immunity transfers to the newborn during the last weeks of pregnancy. RSV vaccination works through the same mechanism, in the same window.

On overstated risk: RSV-related lower respiratory tract disease in infants under three months can mean several days on oxygen in a children’s hospital ward, or occasionally a stint in intensive care. The hospitalisation burden is substantial and well documented. The risk is not hypothetical.

On the trust question: for families who are cautious about vaccine claims — who have watched a lot of pharmaceutical confidence not survive contact with reality — the argument here is worth making carefully. This data comes from an independent research group using hospital surveillance records and the Australian Immunisation Register. It is not a Pfizer press release.

What this data cannot guarantee

Population effectiveness is not individual protection. An 81% reduction in hospitalisation risk at the population level does not mean every vaccinated mother’s baby is protected. It means the population-level risk is substantially reduced. Some infants of vaccinated mothers will still be hospitalised; some infants of unvaccinated mothers will sail through RSV season without incident.

The data also reflects the 2025–26 RSV season. RSV strains shift year to year, and real-world effectiveness can vary between seasons. The honest position is: this is the strongest independent effectiveness evidence available for Australia, and it is good.

My two cents

What is clinically meaningful here is the Australian grounding. Manufacturer efficacy data from global trials has been available for some time — and is genuinely strong — but the question from families and from cautious clinicians has always been: “but does it work like that here, in our hospital system, in our RSV season?”

These data answer that question with a clear signal: yes.

For pregnant women who are still deciding: the evidence now says yes with Australian real-world data behind it. This is not a marginal benefit. An 81% reduction in hospitalisation risk during the period when the only protection your newborn has against RSV is what you transferred before birth is a meaningful, substantial effect.

Verdict: yes — Australian real-world data now backs what the global trials promised.

---

Sources cited

1. Real-world effectiveness of maternal RSV vaccination in Australian infants (peer-reviewed, 2026). https://jamanetwork.com/journals/jamapediatrics/fullarticle/2852944
2. Maternal vaccine cuts RSV hospitalisation risk by 80%. RACGP newsGP, 19 August 2026. https://www1.racgp.org.au/newsgp/clinical/maternal-vaccine-cuts-rsv-hospitalisation-risk-by-80